PMID

Data

Article Title

Organization

A novel series of indazole-/indole-based glucagon receptor antagonists.

Merck Research Laboratories

Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).

Glaxosmithkline

The discovery of N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): a potent and selective glucagon receptor antagonist.

Merck Research Laboratories

Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-ß-alanine (MK-0893) for the treatment of type II diabetes.

Merck Research Laboratories

Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity.

Bristol-Myers Squibb

A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity.

Pfizer

Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.

Merck Research Laboratories

Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists.

Merck Research Laboratories

Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.

Merck Research Laboratories

Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor.

Novo Nordisk

Design and synthesis of conformationally constrained tri-substituted ureas as potent antagonists of the human glucagon receptor.

Merck Research Laboratories

Novel 6-Methoxy-3,4-dihydro-1

Smith, Gambrell & Russell

Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists.

Merck Research Laboratories

Optimization of Truncated Glucagon Peptides to Achieve Selective, High Potency, Full Antagonists.

Indiana University

Optimization of peptide-based polyagonists for treatment of diabetes and obesity.

Novo Nordisk Research Center Indianapolis

Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations.

Sanofi-Aventis Deutschland

Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.

Eberhard Karls University of Tuebingen